A Phase 2a, Ascending Dose, Placebo-Controlled Study to Evaluate the Safety of CTX-100 (Formerly ETX-100) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs CTX 100 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 17 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.